

Renal function improving agent

Drug repositioning of Lubiprostone
Exploratory P2 is over!

Overview

Toxin adsorbents such as SGLT2 inhibitors and cremedin have been used as pharmacotherapy for kidney disease. Lubiprostone, which is also used as a constipation drug, was shown to be effective as a treatment for chronic kidney disease (CKD).

Lubiprostone was also found to suppress the decline in renal function.


In an investigator-initiated clinical trial, the inventors conducted an exploratory study to investigate the efficacy and safety of 8 µg/day and 16 µg/day of lubiprostone in reducing renal function in patients with chronic kidney disease, using a placebo control. (The results can be disclosed under individual contracts.)

Product Application

- ❑ Renal function improving agent
- ❑ Therapeutic agent for chronic kidney disease


IP Data

IP No. : JP6090723
Inventor : ABE Takaaki
Admin No. : T13-090



Renal fibrosis reduced in Lubiprostone group

Features • Outstandings



Levels of renal failure markers were significantly reduced in the Lubiprostone group.

Related Works

J Am Soc Nephrol
. 2015 Aug;26(8):1787-94. doi: 10.1681/ASN.2014060530. Epub 2014 Dec 18.

Contact

Download OnePager



Contact

<https://www.t-technoarch.co.jp/en/contact.html>



Check Out Our Inventions

<https://www.t-technoarch.co.jp/en/anken.php>



Follow us

<https://www.linkedin.com/company/tohoku-techno-arch>



Leading you to Successful Industrialization



TOHOKU TECHNO ARCH

株式会社 東北テクノアーチ